Filling the need for trusted information on national health issues…

  • Your Selections:

Refine Results

date

Topics

Tags

Content Type

medicare-side-by-side-screen-grab

Comparison of Medicare Provisions in Recent Bills and Proposals to Repeal and Replace the Affordable Care Act

Repealing and replacing the Affordable Care Act is a top priority of the Trump Administration and the Republican leadership, which could have implications for the Medicare program. This brief provides a side-by-side comparison of the Medicare-related provisions in six bills and proposals that would repeal the ACA, excluding proposals that would not directly affect Medicare.

Issue Brief Read More
medicare-aca-repeal

What Are the Implications of Repealing the Affordable Care Act for Medicare Spending and Beneficiaries?

The 2010 Affordable Care Act (ACA) included many provisions affecting the Medicare program and the 57 million seniors and people with disabilities who rely on Medicare for their health insurance coverage. This brief explains the Medicare provisions in the ACA and explores the implications for Medicare and beneficiaries of repealing these provisions.

Issue Brief Read More
The Henry J. Kaiser Family Foundation

What Might a Repeal of the Affordable Care Act Mean for Medicare?

As Republican policymakers consider how to repeal and replace the Affordable Care Act (ACA), they are likely to face a number of decisions about whether to retain any of the law’s changes to Medicare. Repealing the ACA has potential implications for Medicare spending, beneficiaries, and other stakeholders, according to a…

News Release Read More
The Henry J. Kaiser Family Foundation

Health Affairs Blog: The Cost Of A Cure: Revisiting Medicare Part D And Hepatitis C Drugs

This blog post revisits an earlier analysis of the drug Sovaldi (sofosbuvir) using new data released by the Centers for Medicare and Medicaid Services, and considers both the ongoing impact of hepatitis C drugs for Medicare Part D and the broader implications for Medicare of new high-priced drugs entering the market.

Perspective Read More
The Henry J. Kaiser Family Foundation

Medicare Part D: A First Look at Prescription Drug Plans in 2017

This issue brief provides an overview of the 2017 Medicare Part D stand-alone prescription drug plan marketplace, based on analysis of data from the Centers for Medicare & Medicaid Services. The brief focuses on data for 2017 and changes over time in plan availability, premiums, benefit design, cost sharing, and low-income subsidy plan availability.

Issue Brief Read More
The Henry J. Kaiser Family Foundation

Medicare Drug Plan Enrollees Would Face an Average 9 Percent Premium Increase Unless They Switch Plans During Open Enrollment, New Analysis Finds

Current enrollees in stand-alone Medicare Part D plans are projected to face an average 9 percent increase in premiums if they remain in their current plan for 2017, according to an analysis released today by the Kaiser Family Foundation. During Medicare’s 2017 open enrollment period, which runs from Oct. 15…

News Release Read More
The Henry J. Kaiser Family Foundation

The Medicare Part D Prescription Drug Benefit

This fact sheet includes the latest information and data for 2017 about the Medicare Part D prescription drug benefit, including current plan information, the standard benefit parameters, low-income assistance, the latest available enrollment data, and Part D program spending and financing.

Fact Sheet Read More
The Henry J. Kaiser Family Foundation

Medicare Part D Spending on the EpiPen Increased More than 1000 Percent from 2007 to 2014

As policymakers in Washington scrutinize the rising cost of the EpiPen auto-injector, a new analysis from the Kaiser Family Foundation shows that Medicare Part D spending for the potentially life-saving device increased by more than 1000 percent between 2007, the year after the Part D drug benefit took effect, and…

News Release Read More
The Henry J. Kaiser Family Foundation

How Much Has Medicare Spent on the EpiPen Since 2007?

This data note examines the effects of rising EpiPen prices on Medicare and beneficiaries. We analyze EpiPen spending, in the aggregate and per user, in Medicare Part D between 2007 (the year after the Part D drug benefit took effect, and the year Mylan acquired the product) and 2014 (the most recent year of data available).

Issue Brief Read More
The Henry J. Kaiser Family Foundation

Medicare Part D in 2016 and Trends over Time

This chartpack presents a summary of Part D enrollment, premiums, cost sharing, benefit design and other key trends in 2016 and changes over time. For 2016, the analysis finds that 40% of Part D enrollees are now in Medicare Advantage drug plans, and over half of all enrollees are in plans offered by just three firms. The chartpack also highlights some concerning trends in the Low-Income Subsidy market, with the fewest number of premium-free plans available since Part D started, and 1.5 million LIS enrollees paying premiums for coverage, even though they have premium-free options available.

Report Read More

The Henry J. Kaiser Family Foundation Headquarters: 2400 Sand Hill Road, Menlo Park, CA 94025 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/KaiserFamFound

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in Menlo Park, California.